Results 1,681-1,700 of 3,336 for speaker:Kate O'Connell
- Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 34 - Housing, Planning and Local Government (28 Feb 2019) Kate O'Connell: I do not have to be as careful as Mr. McCarthy.
- Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 34 - Housing, Planning and Local Government (28 Feb 2019) Kate O'Connell: Really what I am looking at is anything-----
- Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 34 - Housing, Planning and Local Government (28 Feb 2019) Kate O'Connell: I am looking at people leaving the market. In 2012, it was 8,500, going down to 3,250 in 2017. There is a downward trend. There is a narrative that being a private landlord is a very lucrative business. If there was much money in it, people would not be leaving the market.
- Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 34 - Housing, Planning and Local Government (28 Feb 2019) Kate O'Connell: Yes, 86% of them own one or two homes.
- Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 34 - Housing, Planning and Local Government (28 Feb 2019) Kate O'Connell: On the Land Development Agency, there is a narrative that the State is handing loads of lands over to people to build houses for private owners. Will Mr. McCarthy, as quickly as possible, summarise the concept of the Land Development Agency and outline the mix, the minimum social housing proportion, and the plan in that regard? From looking at the figures, I believe social housing is being...
- Public Accounts Committee: 2017 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 34 - Housing, Planning and Local Government (28 Feb 2019) Kate O'Connell: I thank Mr. McCarthy.
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: I thank the witnesses for coming before the committee, for giving of their time and for all they do, particularly Mr. Lawlor. It is very important that patients are out there advocating for others. To follow on from the comments of my colleague, Deputy Durkan, on the EU, I have to agree that the solution here is the EU market and its 500 million people. We are being played off against each...
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: For biosimilars.
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: A few companies were saying that if there are 100 patients with X condition, they would put a top price on annual treatment, such that if there were 102 people, the two extra would be included in the bulk price. I ask the witnesses to expand on the matter. I see this as the market, yet again, ring-fencing a chunk of money so they can say to their shareholders: "We definitely have a return of...
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: This is not my area of expertise. Is it true to say that the mechanism works if it is a population health issue like hepatitis, HIV, HPV or anything that one wants to eradicate?
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: Is it true to say that the mechanism would not necessarily be ideal for a small rare disease patient cohort?
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: Obviously they have their sums done on this.
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: Reference was made, by way of a response, to assessing the impact of treatment be it physiotherapy or home help. We seem to home in on the price of a drug and drug therapies. Obviously we want to cure illness but what about the spectrum between curing and not curing? I ask the witnesses to elaborate on the matter.
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: Inequality is the thing.
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: Provide a package of care.
- Joint Oireachtas Committee on Health: National Medicines Strategy: Discussion (6 Mar 2019)
Kate O'Connell: I thank the witnesses.
- Public Accounts Committee: Oversight and Implementation of Capital Projects and the Role of Public Officials on State Boards: Department of Public Expenditure and Reform and the Office of Government Procurement (7 Mar 2019)
Kate O'Connell: May I ask a quick question?
- Public Accounts Committee: Oversight and Implementation of Capital Projects and the Role of Public Officials on State Boards: Department of Public Expenditure and Reform and the Office of Government Procurement (7 Mar 2019)
Kate O'Connell: Who is the contractor for the Dunkettle roundabout project?
- Public Accounts Committee: Oversight and Implementation of Capital Projects and the Role of Public Officials on State Boards: Department of Public Expenditure and Reform and the Office of Government Procurement (7 Mar 2019)
Kate O'Connell: Am I next?
- Public Accounts Committee: Oversight and Implementation of Capital Projects and the Role of Public Officials on State Boards: Department of Public Expenditure and Reform and the Office of Government Procurement (7 Mar 2019)
Kate O'Connell: I will be quick. Following on from the previous questions, I seek clarification on the issue of the derogation to allow the two-stage tender process to be followed. Are the Dunkettle roundabout and the national children's hospital projects the only two ever to have it applied? I am not sure because Mr. O'Brien said one thing-----